The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.

The mechanism underlying how seasonal allergies recur year after year with precise timing remains largely unknown. An international team led by Professor Rudolf Valenta has identified a specific type ...

When the immune system detects an invader — peanuts, pollen, or another common allergen — it creates immunoglobulin E (IgE) antibodies that spur allergic reactions. Any allergy sufferer can tell you ...

The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company Allows ...

Determining true HER2 status in breast cancers with polysomy using alternative chromosome 17 reference genes: Implications for trastuzumab therapy. Background: Cetuximab is increasingly used in ...

In vitro, omalizumab and human IgE form several immune complexes that vary in size as the 2 components' molar ratios are changed. [29] The largest complex, a stable cyclical hexameric structure ...

It is estimated that around 10% of the US population has peanut allergies, a medical emergency that can be treated but not cured. Compared to those without allergies, these individuals are at a ...